A5068418945- Veterinary Oncology Research
- Virus-based gene therapy research
- Infectious Diseases and Mycology
- Sarcoma Diagnosis and Treatment
- Oral and Maxillofacial Pathology
- Immunotherapy and Immune Responses
- Microbial infections and disease research
- Veterinary Medicine and Surgery
- Gastrointestinal Tumor Research and Treatment
- Inflammatory mediators and NSAID effects
- Polyamine Metabolism and Applications
- Peroxisome Proliferator-Activated Receptors
- Ovarian cancer diagnosis and treatment
- Salivary Gland Tumors Diagnosis and Treatment
- Cancer Research and Treatments
- Cancer and Skin Lesions
- Bladder and Urothelial Cancer Treatments
- Hypertrophic osteoarthropathy and related conditions
- Lymphoma Diagnosis and Treatment
- Veterinary Equine Medical Research
- Cutaneous lymphoproliferative disorders research
- Medical Imaging and Pathology Studies
- Hematopoietic Stem Cell Transplantation
- Mast cells and histamine
- Ear and Head Tumors
University of California, Davis
2013-2023
Veterinary Medical Teaching Hospital
2005-2022
Lankenau Institute for Medical Research
2013
Hospital of the University of Pennsylvania
2005-2013
University of California Office of the President
2010
Executive Office of the President
2010
The University of Texas MD Anderson Cancer Center
2009
University of Pennsylvania
2004-2008
Children's Hospital of Philadelphia
2005
The p53 pathway is critical for tumor suppression, as the majority of human cancer has a faulty p53. Here, we identified RNPC1, target and RNA-binding protein, regulator translation. We showed that ectopic expression RNPC1 inhibited, whereas knockdown increased, translation under normal stress conditions. also prevented cap-binding protein eIF4E from binding mRNA via its C-terminal domain physical interaction with eIF4E, N-terminal mRNA. Consistent this, found directly binds to 5′...
Background : Histiocytic sarcoma is an aggressive neoplasm of dendritic cells that carries a grave prognosis. The efficacy chemotherapy against this disease unknown. purpose study was to determine the 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) in dogs with incompletely resected or metastatic histiocytic sarcoma, describe clinical characteristics these dogs, and identify factors affecting Hypothesis Our hypothesis CCNU has activity canine can improve survival advanced disease....
This study investigates the frequency, location, and clinical findings associated with 177 secondary brain tumors in dogs.Secondary intracranial neoplasia is more common than primary dogs during time period studied, hemangiosarcoma (HSA) most tumor.One hundred seventy-seven client-owned presented to Matthew J. Ryan Veterinary Hospital between 1986 2003.Medical records were searched for a diagnosis of who underwent complete postmortem examination. Of these dogs, those excluded.Of tumors, 51...
Background: Histiocytic sarcoma is an aggressive neoplasm of dendritic cells that carries a grave prognosis. The efficacy chemotherapy against this disease unknown. purpose study was to determine the 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in dogs with incompletely resected or metastatic histiocytic sarcoma, describe clinical characteristics these dogs, and identify factors affecting Hypothesis: Our hypothesis CCNU has activity canine can improve survival advanced disease....
To reexamine (via immunohistochemical techniques) canine tissue samples that had been previously classified as gastrointestinal leiomyosarcomas (GILMSs), identify and differentiate stromal tumors (GISTs) from GILMSs, compare the biological behavior clinical course of GISTs GILMSs in dogs.Retrospective case series.42 dogs.Medical records 42 dogs for which a histologic diagnosis GILMS was confirmed were reviewed signalment, signs, physical examination findings, results initial diagnostic...
Dogs with multicentric T‐cell lymphoma are commonly treated CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone. The purpose of this study was to evaluate the use for dogs lymphoma. Identification prognostic factors in specific subset secondary interest. Twenty‐three out 24 responded these remained on protocol a median 146 days. No variable associated progression free survival (PFS) including stage, substage, hypercalcemia or radiographic...
CHOP-based (cyclophosphamide, doxorubicin, vinca alkaloid, prednisolone) chemotherapy protocols are often recommended for treatment of feline lymphoma. While maintenance-free have been published and readily used in dogs, there is limited literature regarding similar cats. The purpose this study was to describe the outcome cats with intermediate- high-grade lymphoma that were prescribed a modified 25-week University Wisconsin-Madison (UW-25) protocol. A secondary objective examination...
This study reports the outcomes of dogs with grade 3 mast cell tumors (MCTs). Clinical and histopathological data were available for 43 dogs. Median progression-free survival (PFS) overall (OS) 133 257 days, respectively. Tumor size, lymph node (LN) status, mitotic index (MI) significantly influenced PFS in univariate analysis. size LN status remained significant multivariate Lymph local tumor control, treatment, MI OS analysis but only These results confirm that locoregional control...
Histiocytic sarcoma (HS) is associated with a poor prognosis owing to the presence of metastasis at time diagnosis in most dogs. Improved outcome has been reported several dogs localized HS following local therapy, however, distant occurs 70-91% suggesting that adjuvant systemic therapy necessary. The purpose this retrospective study was describe clinical characteristics and treated aggressive plus CCNU chemotherapy. Data from 16 were evaluated. median disease-free interval 243 days. Two had...
Despite numerous published studies describing adjuvant chemotherapy for canine appendicular osteosarcoma, there is no consensus as to the optimal protocol. The purpose of this study was determine whether either two protocols would be associated with longer disease-free interval (DFI) in dogs osteosarcoma following amputation. Dogs histologically confirmed that were free gross metastases and underwent amputation eligible enrollment. randomized receive six doses carboplatin or three each...
Paraneoplastic hypertrophic osteopathy (pHO) is known to occur in both canine and human cancer patients. While the pathology of pHO well-described dog, very little information exists regarding true clinical presentation dogs affected with pHO. The primary objective this study was provide a more comprehensive picture To end, we retrospectively identified 30 recorded data presenting complaints physical examination (PE) findings on date diagnosis. As secondary objective, any blood test results...
Background Reported response rates of transitional cell carcinoma ( TCC ) in dogs to piroxicam combination with either mitoxantrone or carboplatin are similar; however, it is unknown whether drug might provide superior duration response. Hypothesis/Objectives To determine if the progression‐free interval PFI treated and was different than that receiving piroxicam. The hypothesis efficacy no from carboplatin. Animals Fifty without azotemia. Methods Prospective open‐label phase III randomized...
Background Interleukin (IL)-12 is a pro-inflammatory cytokine that mediates T-helper type 1 responses and cytotoxic T-cell activation, contributing to its utility as anti-cancer agent. Systemic administration of IL-12 often results in unacceptable toxicity; therefore, strategies direct delivery tumors are under investigation. The objective this study was assist the preclinical development NHS-IL12, an immunocytokine consisting antibody, which targets necrotic tumor regions, linked IL-12....
The purpose of this study was to evaluate the efficacy and toxicity a single-agent, dose-intensified doxorubicin protocol in canine hemangiosarcoma (HSA). Canine HSA is highly malignant tumor, most affected dogs die within 6 months diagnosis. Doxorubicin most, possibly only, effective chemotherapeutic drug for malignancy, but it provides only moderate improvement survival. On basis previous studies reporting similar survival treated with as single agent doxorubicin-based combination...
The purpose of this study was to evaluate the efficacy and toxicity a single‐agent, dose‐intensified doxorubicin protocol in canine hemangiosarcoma (HSA). Canine HSA is highly malignant tumor, most affected dogs die within 6 months diagnosis. Doxorubicin most, possibly only, effective chemotherapeutic drug for malignancy, but it provides only moderate improvement survival. On basis previous studies reporting similar survival treated with as single agent doxorubicin‐based combination...
Background:Epitheliotropic lymphoma (ELSA) is an uncommon cutaneous canine malignancy of T lymphocytes. A consensus regarding the therapeutic standard care lacking, warranting evaluation chemotherapeutic agents traditionally employed against nodal in treatment ELSA. Hypothesis:The purpose this retrospective, multi‐institutional study was to evaluate efficacy 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) Animals:Forty‐six dogs with adequate follow‐up and response information....
To evaluate changes in characteristics of feline injection-site sarcomas (ISSs) from 1990 through 2006.Retrospective case series.392 cats with a histologic diagnosis soft tissue sarcoma, osteosarcoma, or chondrosarcoma at potential injection sites.Classification and anatomic location tumors signalment affected were compared between ISSs diagnosed before after publication the Vaccine Associated Feline Sarcoma Task Force vaccination recommendations 1996.From to recommendations, proportions...
Increases in liver enzymes occur up to 86% of dogs receiving CCNU and can result treatment delay or early discontinuation treatment. Denamarin contains S-adenosylmethionine silybin, both which have been investigated as treatments for various diseases.Dogs on lower alanine aminotransferase (ALT) activity than not Denamarin. Dogs are less likely require because hepatopathy more complete their prescribed course CCNU.Dogs with lymphoma, mast cell tumor, histiocytic sarcoma that were without...
Immunotherapeutic strategies have shown promise for the treatment of canine osteosarcoma (cOSA). Very little is known about immune microenvironment within cOSA, however, limiting our ability to identify potential targets and biomarkers therapeutic response. We therefore prospectively assessed disease-free interval (DFI) overall survival time (ST) 30 dogs with cOSA treated amputation six doses adjuvant carboplatin. then quantified lymphocytic (CD3+, FOXP3+) macrophage (CD204+) infiltrates...
Purpose Although recombinant human interleukin-15 (rhIL-15) has generated much excitement as an immunotherapeutic agent for cancer, activity in clinical trials been modest to date, part due the risks of toxicity with significant dose escalation. Since pulmonary metastases are a major site distant failure and dog cancers, we sought investigate inhaled rhIL-15 dogs naturally occurring lung from osteosarcoma (OSA) or melanoma. We hypothesized favorable benefit/risk profile given concentrated...
Epitheliotropic lymphoma (ELSA) is an uncommon cutaneous canine malignancy of T lymphocytes. A consensus regarding the therapeutic standard care lacking, warranting evaluation chemotherapeutic agents traditionally employed against nodal in treatment ELSA.The purpose this retrospective, multi-institutional study was to evaluate efficacy 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU) ELSA.Forty-six dogs with adequate follow-up and response information.All cases were diagnosed...
Osteosarcoma is the most common skeletal malignancy in dog and young humans. Although chemotherapy improves survival time, death continues to be attributed metastases. Aerosol delivery can provide a strategy with which improve lung drug while reducing systemic toxicity. The purpose of this study assess safety regional aerosol approach osteosarcoma-bearing dogs, second, evaluate effect gemcitabine on Fas expression pulmonary metastasis.We examined local effects metastasis relevant...
Oral fibrosarcoma (FSA) is a common oral tumour in dogs, and historically reported survival times after surgical excision range from 7.0 to 12.2 months with local recurrence rates of 32–57%. The purpose this retrospective study was report outcome cohort dogs FSA treated or without adjuvant radiation therapy. Twenty‐nine histological diagnosis arising the cavity that underwent resection their were included study. Twenty‐one alone eight both surgery median progression‐free interval >653...
Background Splenic marginal zone lymphoma ( MZL ) is a form of indolent B‐cell that not well characterized in dogs. Hypothesis/Objectives The purpose this study was to describe clinical characteristics and outcome dogs with splenic confirmed by histopathology, immunophenotyping, molecular clonality assessment. We hypothesized affected would have prolonged survival time splenectomy alone. Animals Thirty‐four were included. Twenty‐nine diagnosed after splenectomy, 5 at necropsy. Methods...
Primary pulmonary neoplasia is well recognized in dogs and prognosis depends upon the tumor type. The purpose of this retrospective study was to characterize radiographic appearance different primary lung tumors with goal establishing imaging criteria separate types. Three‐view thoracic radiographs 74 histologically confirmed anaplastic carcinoma ( n = 2), adenocarcinoma 31), bronchioalveolar 19), histiocytic sarcoma 21), squamous cell 1) were evaluated. Radiographs assessed for volume,...